C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Andrea Mancuso,Eugenio Donato Di Paola,Alvaro Leone,Alfonso Catalano,Fabio Calabrò,Linda Cerbone,Andrea Zivi,Carlo Messina,Silvia Alonso,Leonardo Vigna,Rita Caristo,Cora N. Sternberg +11 more
TL;DR: Study Type – Therapy (individual cohort) – Intervention (group cohort) and study type – therapy ( individual cohort)
Journal ArticleDOI
Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study
Evan Y. Yu,George Wilding,Edwin M. Posadas,Mitchell E. Gross,Stéphane Culine,Christophe Massard,Gary R. Hudes,Shinta Cheng,Prashni Paliwal,Cora N. Sternberg +9 more
TL;DR: Anti-proliferative and anti-osteoclastic activity observe in Dasatinib against BCR-ABL and Src-family kinases, EphA2, c-KIT, and PDGFR-β.
Journal ArticleDOI
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.
Daniele Santini,Raffaele Ratta,Francesco Pantano,Delia De Lisi,Marco Maruzzo,Luca Galli,Elisa Biasco,A. Farnesi,Sebastiano Buti,Cora N. Sternberg,Linda Cerbone,Giuseppe Di Lorenzo,Silvia Spoto,Michelle Sterpi,Ugo De Giorgi,Rossana Berardi,Mariangela Torniai,Andrea Camerini,Francesco Massari,Giuseppe Procopio,Giuseppe Tonini +20 more
TL;DR: It is illustrated that continuing the same systemic therapy, after a radical locoregional treatment on a site of progression, seems to be associated with a prolongation of mPFOPOS.
Journal Article
Pazopanib in renal cell carcinoma.
TL;DR: Pazopanib (Votrient, GlaxoSmithKline) has joined existing targeted therapies to provide physicians with a new oral treatment option for their patients with advanced RCC.
Journal ArticleDOI
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.
Melanie Claps,Alessia Mennitto,Valentina Guadalupi,Pierangela Sepe,Marco Stellato,Emma Zattarin,Sommer Silke Gillessen,Cora N. Sternberg,Alfredo Berruti,Filippo de Braud,Elena Verzoni,Giuseppe Procopio +11 more
TL;DR: The present review summarizes the results obtained treating advanced prostate cancer patients with immune-checkpoints inhibitors and analyzes potential mechanisms of both resistance and sensitivity, in order to hypothesize possible avenues of special interest for future research.